Financial Performance Summary

Q2 FY27 Performance:

  • Revenue: ₹1,342 crore, up 31.9% YoY from ₹1,018 crore in Q2 FY26
  • EBITDA: ₹195 crore, up 106% YoY from ₹94 crore in Q2 FY26
  • EBITDA Margin: 14.5% vs 9.3% in Q2 FY26 (520 basis points expansion)
  • PAT: ₹115 crore, up 168% YoY from ₹43 crore in Q2 FY26
  • PAT Margin: 8.4% vs 4.1% in Q2 FY26 (430 basis points expansion)

H1 FY27 Performance:

  • Revenue: ₹2,509 crore, up 22.9% YoY from ₹2,042 crore in H1 FY26
  • EBITDA: ₹369 crore, up 65.3% YoY from ₹223 crore in H1 FY26
  • EBITDA Margin: 14.7% vs 10.9% in H1 FY26 (380 basis points expansion)
  • PAT: ₹216 crore, up 101.9% YoY from ₹107 crore in H1 FY26
  • PAT Margin: 8.4% vs 5.1% in H1 FY26 (330 basis points expansion)

Cost Structure Analysis (Q2 FY27):

  • Cost of goods sold: ₹767 crore
  • Employee Cost: ₹224 crore
  • Other Expenses: ₹157 crore

Segment Performance:

CDMO Business (Q2 FY27):

  • Revenue: ₹1,115 crore, up 38.6% YoY from ₹804 crore in Q2 FY26
  • EBITDA: ₹168 crore, up 99.6% YoY from ₹84 crore in Q2 FY26
  • Performance driven by healthy double-digit volume growth and sustained demand

Strategic Developments

Acquisition:

  • Through wholly owned subsidiary Pure & Cure Healthcare Private Limited, acquired Oriflame India's manufacturing business for ₹56 crore
  • Includes two manufacturing facilities in Roorkee, Uttarakhand and Noida, Uttar Pradesh
  • Includes leased warehouse in Noida
  • Marks Akums' entry into color cosmetics manufacturing
  • Expands capabilities across skincare and wellness products

Management Commentary

Sanjeev Jain, Managing Director:

  • Committed to strengthening position as India's largest CDMO player
  • Demand environment remains robust
  • Continuously investing in manufacturing infrastructure
  • Strengthening capabilities to address evolving requirements
  • Focus on operational excellence, consistent quality, and building long-term relationships

Sandeep Jain, Managing Director:

  • Ambition to establish Akums as globally recognized CDMO player
  • Strengthening product pipeline for global markets
  • Expanding manufacturing capabilities
  • Robust pipeline of over 30+ products for European markets
  • Focus on building diversified and sustainable business combining manufacturing scale, formulation expertise and global quality standards

Financial Data Table

| Particulars (Rs Cr) | Q2 FY 27 | Q1 FY 27 | Q2 FY 26 | H1 FY 27 | H1 FY 26 |

| Revenue | 1,342 | 1,167 | 1,018 | 2,509 | 2,042 |

| Cost of goods sold | 767 | 645 | 593 | 1,412 | 1,174 |

| Employee Cost | 224 | 201 | 189 | 426 | 365 |

| Other Expenses | 157 | 145 | 141 | 302 | 278 |

| EBITDA | 195 | 175 | 94 | 369 | 223 |

| EBITDA Margin | 14.5% | 15.0% | 9.3% | 14.7% | 10.9% |

| PAT | 115 | 101 | 43 | 216 | 107 |

| PAT Margin | 8.4% | 8.4% | 4.1% | 8.4% | 5.1% |

Key Performance Drivers

  • Continued momentum in CDMO business
  • Healthy customer demand
  • Improved operating performance
  • Double-digit volume growth
  • Increasing penetration in Indian pharma market
  • Better operating performance and improved profitability

Future Outlook

  • Focus on expanding manufacturing capabilities
  • Building product pipeline for global markets (30+ products for Europe)
  • Leveraging manufacturing expertise in beauty and personal care industry
  • Building broader and more diversified business platform